Ensol Biosciences
Ensol Biosciences is a clinical-stage South Korean biotech developing first-in-class synthetic peptide drugs across musculoskeletal, oncology, CNS, metabolic, and dermatology indications, using proprietary SSR™ TGF-β modulation and AI platforms (ESAIDD, ETONS), commercialized via licensing and partnership deals.
- Company typePrivate
- Founded2001
- HeadquartersTaejon, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ensol Biosciences does
Ensol Biosciences (엔솔바이오사이언스) is a clinical-stage South Korean biotechnology company developing first-in-class synthetic peptide therapeutics for diseases lacking curative treatment. Founded in 2001 in Daejeon by former ETRI IT expert Kim Hae-jin, the company operates with a research-focused team of 11-50 employees and runs a broad pipeline spanning musculoskeletal (P2K for degenerative disc disease in FDA Phase 3 via Spine BioPharma; E1K for knee osteoarthritis in MFDS Phase 3 in Korea), oncology (C1K/C2K for triple-negative breast cancer and NSCLC; D1K Trop-2-targeting peptide), CNS (M1K for Alzheimer's), metabolic disease (H1K oral obesity peptide), dermatology (A1K for atopic dermatitis), and veterinary health (JointVex/EAD100, approved and marketed in Korea).
The company's core proprietary technology is SSR™ (Signal-path Selective Regulation), which selectively modulates TGF-β signaling pathways to block disease-driving signals while preserving protective ones, addressing the toxicity limitations of complete TGF-β inhibitors. Layered on top are proprietary AI platforms — ESAIDD™ (LLM/ML-based cyclic peptide candidate discovery, validated by the D1K Trop-2 peptide) and ETONS / ETONS 2.0 (an evidence-based molecular interaction database with mechanism-of-action prediction, built over seven years from PubMed text mining and human curation) — that enable a small research team to manage a multi-asset pipeline. A newly announced PRC (Peptide Radiopharmaceutical Conjugate) platform co-developed with Sehan Industries (June 2026) extends the peptide platform into the radiopharmaceutical/theranostics field by addressing linker-cleavage limitations of conventional ADC/PDC approaches.
Commercially, Ensol operates an asset-light licensing-and-partnership model with no direct sales force for human pharma. Revenue streams are milestone- and royalty-based: P2K is licensed to Spine BioPharma ex-Korea with a $155M indication-expansion deal (2024) layered on the original $218M Yuhan-Spine transaction; E1K is exclusively licensed to Humedix for Korea; raw materials are exported to SamaNik in Iran (~10B won over 3 years plus 5% royalty) and to Logistream in Qatar. The company has been KONEX-listed since 2018, is pursuing KOSDAQ relisting after a voluntary December 2023 withdrawal, and is funded through a mix of strategic corporate investors (Yuhan Corporation 4.5B won for 20% stake in 2011, Humedix 5B won in 2023), venture capital (Magna Investment cumulative 3.5B won), and a 20B won founder responsible investment in July 2025.
Ensol Biosciences firmographics
Firmographics- Name
- Ensol Biosciences
- Legal name
- (주)엔솔바이오사이언스
- Website
- https://ensolbio.co.kr
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Ensol Biosciences is a clinical-stage South Korean biotech developing first-in-class synthetic peptide drugs across musculoskeletal, oncology, CNS, metabolic, and dermatology indications, using proprietary SSR™ TGF-β modulation and AI platforms (ESAIDD, ETONS), commercialized via licensing and partnership deals.
- Ownership category
- akta.pro rank
Ensol Biosciences industry classification
Industry- Product category
- Peptide Therapeutics / Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)
Keywords
Where Ensol Biosciences is headquartered
LocationHeadquarters
- HQ city
- Taejon
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
Ensol Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Technology Licensing - P2K: Technology export revenue from P2K (退行性디스크치료제) to Spine BioPharma. Includes non-refundable upfront payment of $5 million, milestone payments totaling $150 million, and 10-year royalty on net sales. Original technology transfer to Yuhan Corporation in 2009, subsequently licensed to Spine BioPharma in 2018, with indication expansion agreement in 2024.
- Material Export - E1K and H1K: Export of raw materials for E1K (골관절염治療劑) and H1K (경구용 비만치료제) to Iran partner SamaNik. Plan to supply materials for 5 years, with expected export value of approximately 10 billion won over 3 years plus 5% royalty on net sales.
- Material Export - H1K to Qatar: Export of oral obesity treatment functional ingredient H1K to Qatar partner Logistream (Al Thani family). Contract for functional food products including H1K and A1K raw materials.
- Strategic Investment: Equity investments from financial partners including Magna Investment (additional 1.5 billion won in August 2024), Humedix (5 billion won in February 2023), and others for R&D funding and operations.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Ensol Biosciences product offering
Product offeringCore offering
Ensol Biosciences develops first-in-class synthetic peptide drugs using proprietary TGF-beta selective modulation technology (SSR) and AI-driven discovery platforms (ESAIDD, ETONS). Its pipeline targets diseases with no effective treatments, including degenerative disc disease (P2K), osteoarthritis (E1K), triple-negative breast cancer (C1K), Alzheimer's (M1K), and obesity (H1K), with revenue generated primarily through technology licensing and royalties to global pharmaceutical partners.
Product overview
Ensol Biosciences is a peptide drug development company operating a platform-plus-pipeline model. Its core AI technology platforms — ESAIDD (AI-based peptide drug candidate discovery using LLM and ML) and ETONS/ETONS 2.0 (AI-based target and MOA prediction) — power a pipeline of first-in-class synthetic peptide drug candidates targeting diseases with no therapeutic alternatives. The pipeline spans musculoskeletal (P2K for degenerative disc disease, E1K for osteoarthritis), oncology (C1K/C2K for triple-negative breast cancer and NSCLC, D1K for Trop-2 targeting), CNS (M1K for Alzheimer's), metabolic (H1K oral obesity), dermatology (A1K for atopic dermatitis), and veterinary medicine (EAD100/JointVex, approved and marketed). The company's proprietary SSR (Signal-path Selective Regulation) technology selectively modulates TGF-β signaling pathways to block disease-driving signals while preserving protective ones. A newly developed PRC (Peptide Radiopharmaceutical Conjugate) platform with Sehan Industry expands into the theranostics field. The company also commercialized the animal osteoarthritis drug JointVex (EAD100) in Korea.
Differentiator
Problem solved
Functional benefit
Brands
- JointVec (조인트벡스): Animal osteoarthritis treatment drug (EAD100) approved and marketed in Korea
- ESAIDD
- ETONS
Products and services
- P2K (Peniel 2000 / SB-01) - Degenerative Disc Disease Treatment First-in-class 7-amino acid synthetic peptide targeting TGF-beta for treatment of degenerative disc disease (DDD). Licensed to Spine BioPharma for global development excluding Korea; currently in FDA Phase 3 clinical trial in the US with 400 patients enrolled. Designed to provide disease-modifying treatment rather than symptom relief for degenerative disc disease.
- E1K (Engedi 1000) - Knee Osteoarthritis Treatment
Companies that use Ensol Biosciences
Customer profileNamed customers2 records
Segments1 record
Ideal customer profiles5 records
Ensol Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
Ensol Biosciences partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and regional.
- Sehan Industries (새한산업)corePRC (Peptide Radioactive Conjugate) co-development agreement signed June 2026 for Trop-2 targeting peptide D1K-based radiopharmaceuticals. Combining Ensol's peptide platform with Sehan's nuclear medicine expertise for cancer therapeutics and theranostics. Addresses linker cleavage limitations of ADC/PDC technologies.
- Daejeon Technopark (대전테크노파크)regionalTrilateral MOU signed March 2026 with Daejeon Metropolitan Government and BioCentury (California) to establish biotech investment gateway connecting local companies with global investors and pharmaceutical partners. Includes investor pitching sessions featuring 11 Daejeon-based companies.
- Spine BioPharma, Inc. (미국 스파인바이오파마)coreP2K indication expansion licensing agreement signed in July 2024. Total deal value of $155 million including $5 million upfront, $150 million milestones, and 10-year royalties on net sales. Rights for additional indications beyond spine (osteoarthritis, fibrotic diseases, oncology). Spine BioPharma also acquired P2K (SB-01) rights from Yuhan Corporation in 2018 for global development excluding Korea.
- Logistream (로직스트림, 카타르)regionalMain contract signed February 2024 for export of H1K (oral obesity treatment) and A1K (anti-aging skincare) raw materials for functional food and cosmetic products. Partner is affiliated with Al Thani royal family in Qatar. Initial product samples delivered, commercial shipments expected to begin.
- SamaNik Salamt Gostar Co. (사마닉, 이란)coreE1K and H1K export contract signed November 2023. SamaNik to conduct Phase 3 clinical trial for E1K in Iran with $5 million funding, plus $1 million success bonus. 5-year supply contract for raw materials with expected export value of approximately 10 billion won over 3 years and 5% royalty on net sales. Also conducting joint clinical trials for C1K and M1K with estimated $23 million funding.
- Humedix (휴메딕스)coreExclusive domestic distribution agreement for E1K (Engedi 1000) knee osteoarthritis treatment in Korea. Also made 5 billion won strategic equity investment in February 2023. Company focusing on strengthening osteoarthritis treatment business.
- Yuhan Corporation (유한양행)coreOriginal co-development partner for YH14618 (P2K) since 2009. Yuhan invested 4.5 billion won for 20% stake in Ensol. Licensed P2K to Spine BioPharma in 2018. P2K milestones of $218 million to be shared at 3:1 ratio between Yuhan and Ensol. Yuhan is second largest shareholder.
Scale indicators12 records
Recent moves4 records
Expansion highlights6 records
Ensol Biosciences competitors and assessment
Company assessmentDirect peers
- PeptiDream: Japanese clinical-stage biopharmaceutical company specializing in peptide drug discovery using its proprietary Peptide Discovery Platform System (PDPS). Directly comparable to Ensol as a peptide-focused platform-plus-pipeline company targeting similar therapeutic areas including metabolic and rare diseases.
- Bicycle Therapeutics: UK clinical-stage biopharma developing bicyclic peptide therapeutics (Bicycles) for oncology and other diseases. Directly comparable as a peptide drug discovery company with proprietary platform technology, multiple clinical-stage assets, and similar modality-focused approach to undruggable targets.
- Protagonist Therapeutics: US clinical-stage biopharma developing peptide-based therapeutics for hematology, inflammation, and immunomodulation. Comparable to Ensol as a peptide platform company with multiple clinical-stage assets targeting diseases with unmet medical needs and similar technology-driven discovery approach.
- Crinetics Pharmaceuticals: US clinical-stage biopharma developing peptide therapeutics for endocrine diseases and rare endocrine disorders. Comparable to Ensol's peptide approach and overlapping metabolic disease focus (H1K obesity), with similar platform-plus-pipeline model and clinical-stage assets.
- Radius Health: US biopharma focused on osteoporosis and metabolic bone diseases with peptide-based therapeutics. Comparable to Ensol's musculoskeletal focus (P2K, E1K) and similar peptide drug modality targeting TGF-β-related pathways and bone/cartilage biology.
- Spine BioPharma: US clinical-stage biopharma developing peptide therapeutics for spine-related degenerative diseases, including the licensed P2K (SB-01) asset. Directly comparable as a peptide-focused company addressing degenerative disc disease with similar target indication and clinical-stage development.
Broad incumbents
- Yuhan Corporation: Major Korean pharmaceutical company and Ensol's second-largest shareholder (12.5% stake, 4.5B won original investment). Comparable as a Korean pharma partner with overlapping therapeutic interests in musculoskeletal and metabolic diseases, and serves as commercialization partner for P2K.
- BioMarin Pharmaceutical: US-based biopharma developing biologics for rare diseases including musculoskeletal and metabolic disorders. Comparable as an established player in biologic therapeutics for similar indications, though significantly larger and more diversified than Ensol.
- Ipsen: Global biopharmaceutical company with peptide therapeutics expertise (e.g., Somatuline for acromegaly, Decapeptyl for prostate cancer). Comparable as an established player in peptide drug development and commercialization, providing industry context for Ensol's peptide platform approach.
Regional players
- Humedix: Korean pharmaceutical company specializing in osteoarthritis treatments and Ensol's exclusive domestic E1K licensee with 50B won strategic investment. Comparable as a Korean musculoskeletal-focused pharma partner with overlapping therapeutic interests and commercial infrastructure for Korean market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Ensol Biosciences social profiles
Digital presenceEnsol Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ensol Biosciences leadership team
Management profileNumber of profiles
Profiles5 records
Ensol Biosciences funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ensol Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ensol Biosciences
What does Ensol Biosciences do?
Ensol Biosciences develops first-in-class synthetic peptide drugs using proprietary TGF-beta selective modulation technology (SSR) and AI-driven discovery platforms (ESAIDD, ETONS). Its pipeline targets diseases with no effective treatments, including degenerative disc disease (P2K), osteoarthritis (E1K), triple-negative breast cancer (C1K), Alzheimer's (M1K), and obesity (H1K), with revenue generated primarily through technology licensing and royalties to global pharmaceutical partners.
Is Ensol Biosciences a public or private company?
Ensol Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ensol Biosciences founded?
Ensol Biosciences was founded in 2001. It employs 11 to 50 people.
Where is Ensol Biosciences based?
Ensol Biosciences is headquartered in Taejon, South Korea, in the Asia region.
How does Ensol Biosciences make money?
Four revenue lines are on record. Technology Licensing - P2K is the primary driver. The others are material Export - E1K and H1K, material Export - H1K to Qatar and strategic Investment.
Who are Ensol Biosciences's main competitors?
Direct peers on record are PeptiDream, Bicycle Therapeutics, Protagonist Therapeutics, Crinetics Pharmaceuticals, Radius Health and Spine BioPharma. Broad incumbents are Yuhan Corporation, BioMarin Pharmaceutical and Ipsen. Humedix is listed as a regional player.
Does Ensol Biosciences have an API?
No public API is recorded for Ensol Biosciences.
What industry is Ensol Biosciences in?
Ensol Biosciences's product category is Peptide Therapeutics / Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 325414 and its SIC code is 2836.